Reduction in the tumor mass has also been reported by using dual therapy with BRAF/MEK inhibitors, i.e., dabrafenib and trametinib, in metastatic ameloblastomas [87, 91] and monotherapy, i.e., dabrafenib or vemurafenib, in recurrent [88–90] and metastatic [92] ameloblastomas. This evidence concerns the gene MAP2K7 and ameloblastoma.